PT-141
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
What is it?
When desire goes quiet, the problem usually isn’t blood flow — it’s the wanting. That’s a brain phenomenon, not a plumbing one, and it’s exactly the gap PT-141 was built to fill. Viagra and its cousins (PDE5 inhibitors) work on the pipes: they dilate blood vessels so an erection can happen once arousal is already there. PT-141 works upstream, in the brain’s wiring, on the desire that precedes the mechanics.
That makes it genuinely distinct. It’s the same reason PT-141 is interesting to both men and women: desire circuitry is shared, and PT-141 acts on it directly. It’s a synthetic cyclic peptide modeled on α-MSH, your body’s own melanocortin hormone — so it’s working with a system you already have, not introducing foreign machinery.
It carries real FDA approval. As Vyleesi, bremelanotide is approved for low sexual desire (HSDD) in premenopausal women, on the strength of two Phase 3 trials. The research-chemical version is the same molecule. That gives PT-141 something most libido products lack: an actual randomized human evidence base.
What does it do in my body?
PT-141 is a non-selective melanocortin receptor agonist, but the receptor that matters for libido is MC4R — concentrated in the medial preoptic area (mPOA) of the hypothalamus, a brain region that runs sexual motivation.
The pathway: PT-141 activates MC4Rs in the mPOA → triggers dopamine release → dopamine drives the “approach/wanting” circuitry of desire. This is a fundamentally different mechanism from PDE5 inhibitors, which never touch desire — they only enable the physical response. PT-141 acts on the upstream signal. The dopamine mechanism is well-mapped in animal models and supported by the human clinical response, with some of the fine wiring still being characterized — normal for a CNS-acting compound.
How can it help me?
- Where the science stands: Phase 3 (RECONNECT, n≈1,267 women) + male Phase 2 + broad real-world use
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
The side-effect profile is the most important practical thing to understand about PT-141 — not because it’s dangerous, but because managing it is the difference between loving the compound and quitting it.
- Nausea is the headline. Around 40% of trial participants reported it, and it’s worst on the first dose. The good news: it’s very manageable. The big levers are dose (start low, ~250–500 mcg), food/timing, and not timing your first dose for a high-stakes occasion — clinicians literally say “don’t take it for the first time on your honeymoon,” because the first dose is the worst and patients acclimate. A simple, natural mitigation some clinicians suggest is ginger + vitamin B6 with the first few doses (the same anti-nausea pairing used in pregnancy). Most people find the nausea fades with subsequent doses as they dial in the right amount.
- Flushing (~20%), headache (~11%), and injection-site reactions (~13%) — generally mild and transient.
- Transient blood-pressure rise with a small heart-rate dip, resolving within ~12 hours. Worth knowing if you have uncontrolled hypertension or known cardiovascular disease — those are the situations to be cautious and talk to a physician.
- Skin/gum darkening (hyperpigmentation) can occur with frequent or higher dosing — a melanocortin class effect, and the same mechanism that makes the related peptide Melanotan II tan the skin. On-demand PT-141 dosing keeps cumulative exposure low.
Bottom line on side effects: PT-141’s profile is well-characterized and the main issue — nausea — is dose-dependent and manageable. Start low, eat something, and most people sail past it.
Regulatory status: FDA-approved as Vyleesi (2019) for acquired, generalized HSDD in premenopausal women. Male use and intranasal use are not FDA-approved indications; the research-chemical powder sold by vendors like Alyve is the same molecule, sold research-use-only, and Alyve states plainly it “is not a pharmacy or compounding facility.” PT-141 is not a WADA-prohibited substance. These are simply the regulatory facts — the molecule is identical across the approved drug and the research-grade powder.
Part 1 — How to reconstitute it
What you'll need: bacteriostatic water (sterile, preserved water you mix the powder with) and a separate, larger reconstitution syringe just for mixing — not the small syringe you inject with.
Reconstitution math (objective): 10 mg ÷ 2 ml = 5 mg/ml = 5,000 mcg/ml. For 500 mcg: 500 ÷ 5,000 = 0.1 ml = 10 units.
How to mix it
- Tilt the vial and let the bacteriostatic water run slowly down the inside glass wall — never squirt it straight onto the powder.
- Swirl gently to dissolve. Never shake — shaking can damage the peptide.
- Store the reconstituted vial refrigerated and out of light.
- Use it within the beyond-use window your source specifies — reconstituted peptides are commonly used within a few weeks; confirm the window for your specific peptide.
Use the free reconstitution calculator to turn any vial size + water volume into exact units on an insulin syringe.
Part 2 — Typical dosing
Talk to your medical provider before starting any protocol. That said, here are the doses most people commonly use — shared for educational purposes so you can have an informed conversation. These peptides are sold for research use only and are not FDA-approved drugs, and this isn't medical advice.
The syringe. Use a 0.3 mL U-100 insulin syringe — it's sized for these small subcutaneous doses. Inject subcutaneously (into the fat just under the skin) and rotate injection sites.
FDA-label dose (Vyleesi): 1.75 mg subcutaneous, at least 45 minutes before sexual activity. Max 1 dose / 24 hours, max 8 doses / month.
Community / practitioner-convention protocol (a commonly used practitioner protocol):
- 10 mg vial, reconstitute with 2 ml bacteriostatic water
- 500 mcg dose, taken ~30 minutes before activity, as needed
- 500 mcg = 0.1 ml = 10 units on a U-100 insulin syringe
Onset and duration (practical). Most users dose 30–60 minutes ahead. Onset of the desire/arousal effect typically lands within 1–3 hours; many report the effect lasting through the evening and sometimes into the next day. It’s an on-demand, as-needed compound — not a daily one.
Where experts differ on dose. The label dose is 1.75 mg; the popular community starting dose is much lower, around 500 mcg. The low-and-slow approach is deliberate — it’s the single most effective lever for managing nausea (see below). Many users start at 250–500 mcg specifically to find the dose that gives the desire effect with the least nausea, then adjust. Lower doses mean less nausea; the trade-off is they may also mean a milder effect, so it’s a personal titration.
Route: subcutaneous vs intranasal. The approved product and most community use is subcutaneous. PT-141 was historically also developed as an intranasal spray (much of the early male ED trial work used the nasal route: Safarinejad 2008, Diamond 2006). The practical trade-off clinicians describe: subcutaneous = slightly slower onset, longer duration; intranasal = faster onset, shorter duration. Pick the route to fit the use case (fast-and-short vs slower-and-longer).
Where PT-141 won’t help (patient selection). Because PT-141 acts on desire and central arousal, it doesn’t fix a purely mechanical erection problem. In men with post-prostatectomy / post-prostate-cancer ED: where the nerves/plumbing themselves are the issue rather than the brain signal — PT-141 may still improve desire but won’t restore erectile function. The clinic framing is a success triad: the right condition + the right patient + the right (titrated) dose. PT-141 is a desire tool; it’s not a substitute for PDE5 inhibitors, Trimix, or hormone replacement when those are the actual gap.
What should I avoid combining — and what's synergistic?
Stacking. PT-141 is most often used standalone, on-demand. Some users in the libido/sexual-health lane combine it situationally with PDE5 inhibitors (Viagra/Cialis): the Diamond 2005 logic of desire + blood flow, hitting two different parts of the response. Clinicians report PT-141 can improve the efficacy of a PDE5 inhibitor in men getting suboptimal results from the PDE5 drug alone. This makes PT-141 an enhancer, not just a replacement, for the large PDE5-inhibitor-user audience.
How can I buy this?
- Product: PT-141: $19.99 (5 mg) / $41.00 (10 mg) — currently OUT OF STOCK (check for restock)
- COA: No certificate of analysis on disk for the PT-141 line yet. Alyve’s other tested SKUs run >99% via Freedom Diagnostics; for PT-141 that third-party verification isn’t on file here — worth confirming when it restocks.
- Specs: CAS 189691-06-3; C50H68N14O10; MW 1025.18 g/mol; white lyophilized powder; store −20°C
- Alyve’s copy describes it as “a melanocortin receptor agonist reference compound” and makes no libido claims. (Filed on-site under “Copper Peptide Research” — a taxonomy quirk; PT-141 is not a copper peptide.)
CTA: Use code OHM-15 for 15% off — Alyve’s pricing is very competitive, and buying 3 vials of any given peptide in one purchase gets you over 30% off retail. PT-141 is out of stock at the moment, so this applies on restock; among in-stock melanocortin options see Melanotan II (same receptor family, different use).
When you use my coupon code to buy peptides with these sellers, you enjoy a discount off retail price, and I make a small commission which helps me to continue to offer this peptide educational site to you for free. I only have affiliate relationships with peptide manufacturers that show evidence that their peptides are 100% manufactured in the US, 3rd party lab tested for purity, transparent COAs posted on their websites, and that have good customer service.
PT-141 works on desire itself — in the brain, not the plumbing. It’s the centrally-acting libido peptide: a melanocortin agonist that boosts dopamine signaling in the brain’s sexual-motivation circuitry. It carries real FDA approval (as Vyleesi, for low sexual desire in premenopausal women) and the same molecule is sold research-use-only by vendors like Alyve. This is the full information picture — mechanism, the actual trial numbers, the real-world protocol, and the honest nausea reality.
| Class | Synthetic cyclic heptapeptide; melanocortin receptor agonist (analog of α-MSH) |
| Mechanism (one line) | Activates MC4R in the brain’s medial preoptic area → boosts dopamine signaling → increases sexual DESIRE centrally (not blood flow) |
| Route | Subcutaneous injection (approved); intranasal historically |
| Half-life | ~2.7 hours |
| Evidence base | Phase 3 (RECONNECT, n≈1,267 women) + male Phase 2 + broad real-world use |
| Regulatory status | FDA-approved 2019 (Vyleesi) for premenopausal HSDD. Research-chemical form is the same molecule, sold for research use |
| Alyve product | PT-141 — $19.99 (5mg) / $41.00 (10mg) — currently OUT OF STOCK — no COA on disk yet |
| Primary use case | Low sexual desire; centrally-acting, distinct from Viagra-type blood-flow drugs |
What it is
When desire goes quiet, the problem usually isn’t blood flow — it’s the wanting. That’s a brain phenomenon, not a plumbing one, and it’s exactly the gap PT-141 was built to fill. Viagra and its cousins (PDE5 inhibitors) work on the pipes: they dilate blood vessels so an erection can happen once arousal is already there. PT-141 works upstream, in the brain’s wiring, on the desire that precedes the mechanics.
That makes it genuinely distinct. It’s the same reason PT-141 is interesting to both men and women: desire circuitry is shared, and PT-141 acts on it directly. It’s a synthetic cyclic peptide modeled on α-MSH, your body’s own melanocortin hormone — so it’s working with a system you already have, not introducing foreign machinery.
It carries real FDA approval. As Vyleesi, bremelanotide is approved for low sexual desire (HSDD) in premenopausal women, on the strength of two Phase 3 trials. The research-chemical version is the same molecule. That gives PT-141 something most libido products lack: an actual randomized human evidence base.
How it works
PT-141 is a non-selective melanocortin receptor agonist, but the receptor that matters for libido is MC4R — concentrated in the medial preoptic area (mPOA) of the hypothalamus, a brain region that runs sexual motivation.
The pathway: PT-141 activates MC4Rs in the mPOA → triggers dopamine release → dopamine drives the “approach/wanting” circuitry of desire. This is a fundamentally different mechanism from PDE5 inhibitors, which never touch desire — they only enable the physical response. PT-141 acts on the upstream signal. The dopamine mechanism is well-mapped in animal models and supported by the human clinical response, with some of the fine wiring still being characterized — normal for a CNS-acting compound.
What the research shows
PT-141 is one of the better-evidenced peptides in this catalog, with both approval-grade female data and Phase 2 male data.
** The approval data (women).** Two Phase 3 double-blind RCTs (RECONNECT, combined n≈1,267 premenopausal women with HSDD) met both co-primary endpoints: statistically significant improvement in sexual desire (FSFI desire domain) and a reduction in desire-related distress versus placebo. That’s the basis for the 2019 Vyleesi approval. The full RECONNECT program is well-documented: prespecified integrated subgroup analyses (n=1,202) showed the desire/distress benefit held consistently across age, weight, BMI, and bioavailable-testosterone subgroups, and a pooled safety review across the entire clinical-development program (3,500 subjects, 43 studies; phase-3 integrated n=1,247) characterized the AE profile in detail. A 2025 systematic review and meta-analysis of treatment options for female sexual dysfunction places bremelanotide among the evidence-supported pharmacologic options [META — Toledo 2025, PMID 40543759]. The effect is real and statistically significant; in magnitude it’s a meaningful bump for responders rather than a switch-flip for everyone, with satisfying-sexual-events rising on drug vs. placebo. As with most desire interventions, some women respond strongly and some don’t — which is why the protocol is “try it, keep it if it works for you.”
** Men / erectile and desire response.** Phase 2 RCTs in men are genuinely positive. Safarinejad 2008 (n=342, intranasal, in men who’d failed sildenafil) found a 33.5% response vs. 8.5% placebo. Diamond 2005 studied PT-141 combined with sildenafil and found additive benefit. A full Phase 3 male program wasn’t completed and there’s no male FDA approval, so male use draws on this Phase 2 base plus the large real-world community that uses it — but the Phase 2 signal is the same direction as the approved female data.
** Real-world use.** PT-141 is widely used by both men and women in the peptide community, typically on-demand before activity. Users report an onset of desire and arousal within a couple of hours and effects that can persist well into the next day. This is anecdotal/clinical-observation tier, but it’s a large and consistent body of real-world reporting that lines up with the trial mechanism.
Where reporting and re-analysis differ: the honest effect-size debate. An independent re-analysis of the female trial data (Spielmans) argued that the published reports emphasized favorable outcomes, that average effect sizes were modest, and that AE-driven discontinuation was higher on drug. The trial investigators published a direct rebuttal contesting that re-analysis [— Kingsberg et al. 2021, J Sex Res, PMID 33835907], and a regulatory-context critique (Mintzes 2021) likewise framed the average benefit as small [REVIEW — PMID 34642243]. This is a genuine, live disagreement worth surfacing in full: the approval and the MC4R mechanism are solid; what’s contested is how big the average effect is versus how meaningful it is for the responders who keep using it. Both sides are in the published record — that’s the honest landscape, and it’s exactly the kind of expert disagreement that makes for strong content rather than a disqualifier.
Real-world protocol
The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.
FDA-label dose (Vyleesi): 1.75 mg subcutaneous, at least 45 minutes before sexual activity. Max 1 dose / 24 hours, max 8 doses / month.
Community / practitioner-convention protocol (a commonly used practitioner protocol):
- 10 mg vial, reconstitute with 2 ml bacteriostatic water
- 500 mcg dose, taken ~30 minutes before activity, as needed
- 500 mcg = 0.1 ml = 10 units on a U-100 insulin syringe
Reconstitution math (objective): 10 mg ÷ 2 ml = 5 mg/ml = 5,000 mcg/ml. For 500 mcg: 500 ÷ 5,000 = 0.1 ml = 10 units.
Onset and duration (practical). Most users dose 30–60 minutes ahead. Onset of the desire/arousal effect typically lands within 1–3 hours; many report the effect lasting through the evening and sometimes into the next day. It’s an on-demand, as-needed compound — not a daily one.
Where experts differ on dose. The label dose is 1.75 mg; the popular community starting dose is much lower, around 500 mcg. The low-and-slow approach is deliberate — it’s the single most effective lever for managing nausea (see below). Many users start at 250–500 mcg specifically to find the dose that gives the desire effect with the least nausea, then adjust. Lower doses mean less nausea; the trade-off is they may also mean a milder effect, so it’s a personal titration.
Route: subcutaneous vs intranasal. The approved product and most community use is subcutaneous. PT-141 was historically also developed as an intranasal spray (much of the early male ED trial work used the nasal route: Safarinejad 2008, Diamond 2006). The practical trade-off clinicians describe: subcutaneous = slightly slower onset, longer duration; intranasal = faster onset, shorter duration. Pick the route to fit the use case (fast-and-short vs slower-and-longer).
Stacking. PT-141 is most often used standalone, on-demand. Some users in the libido/sexual-health lane combine it situationally with PDE5 inhibitors (Viagra/Cialis): the Diamond 2005 logic of desire + blood flow, hitting two different parts of the response. Clinicians report PT-141 can improve the efficacy of a PDE5 inhibitor in men getting suboptimal results from the PDE5 drug alone. This makes PT-141 an enhancer, not just a replacement, for the large PDE5-inhibitor-user audience.
Where PT-141 won’t help (patient selection). Because PT-141 acts on desire and central arousal, it doesn’t fix a purely mechanical erection problem. In men with post-prostatectomy / post-prostate-cancer ED: where the nerves/plumbing themselves are the issue rather than the brain signal — PT-141 may still improve desire but won’t restore erectile function. The clinic framing is a success triad: the right condition + the right patient + the right (titrated) dose. PT-141 is a desire tool; it’s not a substitute for PDE5 inhibitors, Trimix, or hormone replacement when those are the actual gap.
Side effects & management
The side-effect profile is the most important practical thing to understand about PT-141 — not because it’s dangerous, but because managing it is the difference between loving the compound and quitting it.
- Nausea is the headline. Around 40% of trial participants reported it, and it’s worst on the first dose. The good news: it’s very manageable. The big levers are dose (start low, ~250–500 mcg), food/timing, and not timing your first dose for a high-stakes occasion — clinicians literally say “don’t take it for the first time on your honeymoon,” because the first dose is the worst and patients acclimate. A simple, natural mitigation some clinicians suggest is ginger + vitamin B6 with the first few doses (the same anti-nausea pairing used in pregnancy). Most people find the nausea fades with subsequent doses as they dial in the right amount.
- Flushing (~20%), headache (~11%), and injection-site reactions (~13%) — generally mild and transient.
- Transient blood-pressure rise with a small heart-rate dip, resolving within ~12 hours. Worth knowing if you have uncontrolled hypertension or known cardiovascular disease — those are the situations to be cautious and talk to a physician.
- Skin/gum darkening (hyperpigmentation) can occur with frequent or higher dosing — a melanocortin class effect, and the same mechanism that makes the related peptide Melanotan II tan the skin. On-demand PT-141 dosing keeps cumulative exposure low.
Bottom line on side effects: PT-141’s profile is well-characterized and the main issue — nausea — is dose-dependent and manageable. Start low, eat something, and most people sail past it.
Regulatory status
FDA-approved as Vyleesi (2019) for acquired, generalized HSDD in premenopausal women. Male use and intranasal use are not FDA-approved indications; the research-chemical powder sold by vendors like Alyve is the same molecule, sold research-use-only, and Alyve states plainly it “is not a pharmacy or compounding facility.” PT-141 is not a WADA-prohibited substance. These are simply the regulatory facts — the molecule is identical across the approved drug and the research-grade powder.
The Alyve product
- Product: PT-141: $19.99 (5 mg) / $41.00 (10 mg) — currently OUT OF STOCK (check for restock)
- COA: No certificate of analysis on disk for the PT-141 line yet. Alyve’s other tested SKUs run >99% via Freedom Diagnostics; for PT-141 that third-party verification isn’t on file here — worth confirming when it restocks.
- Specs: CAS 189691-06-3; C50H68N14O10; MW 1025.18 g/mol; white lyophilized powder; store −20°C
- Alyve’s copy describes it as “a melanocortin receptor agonist reference compound” and makes no libido claims. (Filed on-site under “Copper Peptide Research” — a taxonomy quirk; PT-141 is not a copper peptide.)
CTA: Use code OHM-15 for 15% off — Alyve’s pricing is very competitive, and buying 3 vials of any given peptide in one purchase gets you over 30% off retail. PT-141 is out of stock at the moment, so this applies on restock; among in-stock melanocortin options see Melanotan II (same receptor family, different use).
Sources
- : 31429064 — Bremelanotide: First Approval (RECONNECT summary)
- : 33455598 — Neurobiology / MC4R mechanism
- : 17958619 — Preclinical female (rat) dopamine mechanism
- : 18206919 — Safarinejad 2008, male ED Phase 2
- : 15833522 — Diamond 2005, PT-141 + sildenafil
- : 31893927 — Systematic review (AE rates)
- : 35230162 — Simon 2022, RECONNECT phase-3 integrated subgroup analyses (J Womens Health)
- : 35147466 — Clayton 2022, safety across the clinical-development program (J Womens Health)
- : 40543759 — Toledo 2025, systematic review + meta-analysis of FSD treatments
- : 33678061 — Spielmans 2021, RECONNECT re-analysis
- : 36809187 — Spielmans & Ellefson 2024, outcome-validity critique
- : 33835907 — Kingsberg et al. 2021, rebuttal to Spielmans (J Sex Res)
- : 34642243 — Mintzes 2021, regulatory-context critique
- LiverTox (NIH) — https://www.ncbi.nlm.nih.gov/books/NBK573221/
- : 16839319 — Diamond 2006, intranasal bremelanotide in women with sexual arousal disorder
- Alyve product page — https://alyvepeptides.com/product/pt-141/
- (0019 corpus, 118 records / 14 RCTs / 3 meta-analyses),
-
- (RevitalizeMD clinic) — clinical-practice detail: PDE5-inhibitor synergy, intranasal-vs-subQ route trade-offs, ginger+B6 nausea mitigation + first-dose-timing, and the mechanical-vs-neurogenic (post-prostatectomy) patient-selection point. Clinic-funnel framing surfaced + not inherited per KB doctrine.
Sources & references
- : 31429064 — Bremelanotide: First Approval (RECONNECT summary)
- : 33455598 — Neurobiology / MC4R mechanism
- : 17958619 — Preclinical female (rat) dopamine mechanism
- : 18206919 — Safarinejad 2008, male ED Phase 2
- : 15833522 — Diamond 2005, PT-141 + sildenafil
- : 31893927 — Systematic review (AE rates)
- : 35230162 — Simon 2022, RECONNECT phase-3 integrated subgroup analyses (J Womens Health)
- : 35147466 — Clayton 2022, safety across the clinical-development program (J Womens Health)
- : 40543759 — Toledo 2025, systematic review + meta-analysis of FSD treatments
- : 33678061 — Spielmans 2021, RECONNECT re-analysis
- : 36809187 — Spielmans & Ellefson 2024, outcome-validity critique
- : 33835907 — Kingsberg et al. 2021, rebuttal to Spielmans (J Sex Res)
- : 34642243 — Mintzes 2021, regulatory-context critique
- LiverTox (NIH) — https://www.ncbi.nlm.nih.gov/books/NBK573221/
- : 16839319 — Diamond 2006, intranasal bremelanotide in women with sexual arousal disorder
- Alyve product page — https://alyvepeptides.com/product/pt-141/
- (0019 corpus, 118 records / 14 RCTs / 3 meta-analyses),
-
- (RevitalizeMD clinic) — clinical-practice detail: PDE5-inhibitor synergy, intranasal-vs-subQ route trade-offs, ginger+B6 nausea mitigation + first-dose-timing, and the mechanical-vs-neurogenic (post-prostatectomy) patient-selection point. Clinic-funnel framing surfaced + not inherited per KB doctrine.